Signum Surgical

Executive Summary

Signum Surgical is an Irish medical device company founded in 2015 and headquartered in Galway, dedicated to developing minimally invasive solutions for colorectal care. The company's lead product, BioHealx, is an implant designed to treat anal fistula by closing the fistula tract through tissue apposition while preserving sphincter function and reducing recurrence. Anal fistula is a common condition with high unmet need, as current surgical options often compromise sphincter integrity or have high recurrence rates. Signum's technology aims to offer a safer, more effective alternative, addressing a market estimated at over $1 billion globally. The company is privately held and has not yet disclosed total funding or valuation, but its focus on a validated preclinical and early clinical pathway positions it for potential regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical trial with primary endpoint data60% success
• Q1 2027FDA 510(k) clearance or CE mark application submission50% success
• Q2 2026Series B or strategic partnership funding round70% success